J&J Buys Aragon, Boosting Prostate Cancer Franchise Beyond Zytiga
This article was originally published in The Pink Sheet Daily
Executive Summary
The buyout gives J&J Aragon’s androgen receptor inhibitor similar to Medivation’s Xtandi, a potential blockbuster and competitor. In the process, Aragon’s investors will back new spinout Seragon, created to house an estrogen receptor blocker.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2013
The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.
Aisling, Clarus Make Huge Bets On Royalties
When was the last time a life science venture firm spent close to $50 million all in one go? It doesn't happen often, but Aisling Capital and Clarus Ventures have each put up $48.5 million for a tiny slice of sales royalties from ibrutinib, a promising cancer drug that could receive FDA approval this calendar year or early next.
J&J Highlights Late-Stage R&D Prospects Across Pharma Division
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.